Heart failure is a chronic progressive disease that affects millions of people in the United States. Although medical management of heart failure has helped improve quality of life and survival, end-stage heart failure ultimately requires a heart transplant or long-term left ventricular assist device (LVAD) support. With more patients awaiting transplant, the demand for hearts outweighs the supply of donor hearts. The use of LVADs is increasing in patients with advanced heart failure as a treatment option for those awaiting a heart transplant or as a long-term solution if they are ineligible for a transplant. Although the LVAD is a marvel of modern medicine, infection is a cause of concern because today’s LVADs are powered externally through a percutaneous driveline that can be a major source of infection.
Skip Nav Destination
Article navigation
1 October 2015
Feature|
October 01 2015
Left Ventricular Assist Device Driveline Infections: The Achilles’ Heel of Destination Therapy
Marc Angud, RN, BSN, PCCN-CMC
Marc Angud, RN, BSN, PCCN-CMC
Marc Angud is Adult-Gerontology Acute Care Nurse Practitioner Student, Thomas Jefferson University College of Nursing, 901 Walnut Street, Suite 823, Philadelphia, PA 19107 ([email protected]).
Search for other works by this author on:
AACN Adv Crit Care (2015) 26 (4): 300–305.
Citation
Marc Angud; Left Ventricular Assist Device Driveline Infections: The Achilles’ Heel of Destination Therapy. AACN Adv Crit Care 1 October 2015; 26 (4): 300–305. doi: https://doi.org/10.4037/NCI.0000000000000108
Download citation file:
Sign in
Don't already have an account? Register
Short-term Access
Purchase short-term access on a pay-per-article or pay-per-issue basis.
$15 72 - hour single article access $30 7 - day full issue access